Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : HD-6277
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HD-6277 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetes Mellitus, Type 2.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 18, 2024
Lead Product(s) : HD-6277
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ezetimibe is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hypertension.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 17, 2024
Lead Product(s) : Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Empagliflozin
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Kyungpook National University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Empagliflozin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 2.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 29, 2024
Lead Product(s) : Empagliflozin
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Kyungpook National University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clascoterone
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Recipient : Cosmo Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Cosmo and Hyundai Pharm Announce Signing of License Agreement for Winlevi® in Korea
Details : Under the license agreement terms, Hyundai Pharm will receive from Cosmo, the exclusive right to commercialize Winlevi (clascoterone) in the Republic of Korea, which is indicated for acne vulgaris.
Product Name : Winlevi
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 22, 2023
Lead Product(s) : Clascoterone
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Recipient : Cosmo Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : BPDO-1603
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetics of BPDO-1603 or BPDO-16031 and BPDO-16033 Administration in Healthy Adults
Details : BPDO-1603 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 07, 2023
Lead Product(s) : BPDO-1603
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LINO-1713
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LINO-1713 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Contraception.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 10, 2023
Lead Product(s) : LINO-1713
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HD-6277
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HD-6277 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetes Mellitus, Type 2.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 27, 2022
Lead Product(s) : HD-6277
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HDDO-1756
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
HDDO-1756 Bio Equivalence Study
Details : HDDO-1756 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hyperlipidemias.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 16, 2021
Lead Product(s) : HDDO-1756
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
BPDO-1603 Intervention Trial in Patients With Moderate-to-severe Alzheimer's Disease
Details : BPDO-1603 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 18, 2020